Skip to main content
Clinical Trials/EUCTR2004-003807-19-HU
EUCTR2004-003807-19-HU
Active, not recruiting
Not Applicable

A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia - Ezetimibe/Simvastatin and Fenofibrate Coadministration Study

Merck & Co., Inc.0 sites600 target enrollmentOctober 28, 2004

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Mixed hyperlipidemia
Sponsor
Merck & Co., Inc.
Enrollment
600
Status
Active, not recruiting
Last Updated
13 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 28, 2004
End Date
TBD
Last Updated
13 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • a.Patient has an LDL\-C 130 through 220 mg/dL (3\.37 through 5\.70 mmol/L) for non\-diabetics; LDL\-C 100 through 180 mg/dL (2\.59 through 4\.66 mmol/L) for diabetics, at Visit 2\.
  • b.Patient has triglycerides 150 through 500 mg/dL (1\.71 through 5\.70 mmol/L). \[per central laboratory reference ranges] at Visit 2\.
  • c.Patient has creatine phosphokinase (CPK) \=2 x upper limit of normal (ULN) \[per central laboratory reference ranges] at Visit 2\.
  • d.Patient has alanine aminotransferase (ALT), and aspartate aminotransferase (AST) \=1\.5 x upper limit of normal (ULN) \[per central laboratory reference ranges] at Visit 2\.
  • Are the trial subjects under 18?
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • a.You are less than 18 years of age or greater than 79 years of age.
  • b.You are pregnant, breastfeeding, or planning to become pregnant during this study.
  • c.You are a woman able to become pregnant and are not willing to use an acceptable method of birth control. You must be willing to use this birth control starting at Visit 1 and continuing 14 days past the last study dose. The study doctor or staff will discuss which methods of birth control are acceptable for this study.
  • d.You are a woman and have taken cyclical hormone birth control or hormone replacement within 8 weeks of Visit 3\.
  • e.You have chronic heart failure, uncontrolled irregular heart beats or a history of heart disease. The study doctor or staff will discuss this with you.
  • f.You have diabetes and are taking lipid lowering medication called statins.
  • g.You have a history of cholelithiasis (gallbladder problems) and you have not had your gallbladder removed.
  • h.You have an active liver disease.
  • i.You are HIV positive.
  • j.You have a history of cancer with in the past 5 years (except for skin cancer that has been successfully treated).

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia - Ezetimibe/Simvastatin and Fenofibrate Coadministration Study
EUCTR2004-003807-19-ESMerck & Co Inc.600
Active, not recruiting
Not Applicable
A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia - Ezetimibe/Simvastatin and Fenofibrate Coadministration StudyMixed hyperlipidemiaMedDRA version: 7.0Level: LLTClassification code 10027762
EUCTR2004-003807-19-ATMerck, Sharp & Dohme600
Active, not recruiting
Phase 1
A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia - Ezetimibe/Simvastatin and Fenofibrate Coadministration StudyMixed hyperlipidemiaMedDRA version: 7.0 Level: LLT Classification code 10027762
EUCTR2004-003807-19-GBMerck Sharp & Dohme Ltd600
Completed
Not Applicable
The study for beneficial efficacy and safety of ezetimibe in patients with hyper LDL-cholesterolemia associated with diabetes mellitus (DM) including glucose intolerance and non-alcoholic fatty liver disease (NAFLD)non-alcoholic fatty liver disease, diabetes mellitus, hyper LDL-cholesterolemia
JPRN-UMIN000004462Geriatric Medicine, Osaka University Graduate School of Medicine20
Not yet recruiting
Phase 2
Exploratory survey of the safety and efficacy of endoscopic radiofrequency ablation for malignant biliary strictureMalignant biliary stricture
JPRN-UMIN000031601Graduate School of Medicine, Chiba University10